PNPolina A. Naymushina

Polina A. Naymushina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Polina A. Naymushina has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effectiveness of local methods of treatment in patients with germ cell tumors who have exhausted all curative options of systemic therapy. Clinical case report and literature review

    by Polina A. Naymushina, Наймушина Полина Андреевна, M. A. Toporkov, Топорков М. А., L. L. Rabaeva, Рабаева Л. Л., M. M. Strozhenkov, Строженков М. М., N. V. Zhukov, Жуков Н. В.

    Introduction. With adequate initial therapy, germ cell tumors (GCTs) have a relatively favorable prognosis; however, approximately 20–25% of patients experience relapse or refractory disease. Currently, there are several potentially curative treatment options for this patient population but the optimal approach remains undetermined in both adult and pediatric practice. A particular challenge is the management of patients who have not responded to multiple lines of systemic therapy. Although most GCTs are considered as a primarily systemic disease, in this population with an extremely low chance of cure with systemic treatment alone, local control modalities may offer a chance of cure. Clinical experience demonstrates the effectiveness of not only surgical but also radiotherapeutic approaches, despite the fact that non-seminomatous/non-dysgerminomatous GCTs were previously considered radioresistant. Clinical case. Here, we report a clinical case of a 16-year-old female adolescent with secreting malignant ovarian germ cell tumor. The patient received 3 cycles of multi-agent chemotherapy according to the MAKEI-05 protocol, followed by surgical treatment (left-sided salpingo-oophorectomy). After surgery, a radiological complete response was achieved, however, alpha-fetoprotein (AFP) levels did not normalize. Later, the patient showed a rise in AFP levels and a metabolically active tumor on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Therefore, second-line therapy was administered according to the TIGER protocol, after which AFP levels normalized. One month after the completion of multi-modal treatment, an increase in AFP was observed, and PET/CT again revealed metabolically active lesions. To achieve systemic disease control, the girl received chemotherapy with the GOP regimen (gemcitabine, oxaliplatin, paclitaxel), followed by surgical exploration of the abdominal cavity, which revealed no pathological findings. Given the inability to rule out the presence of viable tumor cells, a multidisciplinary decision was made to administer radiation therapy to the metabolically active lesions visualized on PET/CT (in the region of the right uterine adnexa). The patient underwent radiation therapy to the right adnexal bed to a total dose of 50.4 Gy. The girl was discharged for follow up. At the time of this report, the patient remains in complete unmaintained remission for 30 months. Conclusion. This clinical case illustrates successful curative local treatment of the patient with recurrent disease after multiple surgeries in the same area, who had exhausted all available systemic curative options.

  • Open Access

    Tandem hematopoietic stem cell transplantation in children with solid tumors in the Russian Federation: results of a retrospective multicenter study

    by D. S. Smirnova, K. I. Kirgizov, I. V. Kazantsev, S. A. Kulyova, P. S. Tolkunova, Yu. V. Dinikina, A. Yu. Smirnova, S. I. Lapaeva, T. Z. Aliev, G. B. Sagoyan, et al.

    Relevance. Despite the overall decline in the use of auto-HSCT, there remains a need for treatment intensification in pediatric patients with highrisk solid tumors. Tandem auto-HSCT represents a promising approach to improve therapeutic efficacy, but its toxicity and impact on long-term outcomes require further investigation, particularly in the Russian patient population.The aim of study – to evaluate the feasibility, toxicity, and long-term outcomes of tandem autologous hematopoietic stem cell transplantation (auto-HSCT) in children with high-risk solid malignant neoplasms in the Russian Federation.Materials and methods. This retrospective multicenter study included 108 (100 %) pediatric patients (median age – 2 years) with solid malignant neoplasms who underwent tandem high-dose chemotherapy with auto-HSCT at 9 centers in the Russian Federation (2004–2024). Main diagnoses included brain tumors – n = 66 (61.1 %), germ cell tumors – n = 25 (23 %), and neuroblastoma – n = 12 (11.1 %). Toxicity was assessed using CTCAE v5.0 criteria, and survival analysis was performed using the Kaplan–Meyer method.Results. The most common complications were febrile neutropenia (88.9 %) and oropharyngeal mucositis (87.1 %), with severe toxicities (Grade 3–4) being rare. The 3-year overall survival was 72.2 %, and event-free survival was 62.7 %.Conclusion. The study demonstrated that tandem auto-HSCT is a feasible procedure with manageable toxicity. These findings suggest the potential of tandem auto-HSCT for children with high-risk solid tumors, though further prospective studies with long-term outcome assessments are needed to define optimal indications.


  • Open Access

    Thyroid gland ectopia to the ovary resulting in papillary thyroid cancer with carcinomatosis

    by P. A. Naymushina, D. V. Shevtsov, N. G. Uskova, D. S. Abramov, D. M. Konovalov, D. G. Akhaladze, N. S. Grachev

    Thyroid gland ectopia is a rare condition occurring as a developmental anomaly during the embryonic period, when the thyroid primordium migrates. The prevalence of thyroid gland ectopia is 1 per 100 000–300 000 healthy individuals. Struma ovarii is a variant of thyroid gland ectopia, defined by the presence of thyroid tissue in the ovary. Cases of struma ovarii are very rare, and in the pediatric population they are even more rare than in adults. Only a few cases of struma ovarii in patients under 18 years have been described in the literature. Here, we present a clinical case of papillary thyroid cancer in ectopic thyroid tissue in a 13-year-old girl. The patient's parents gave their consent to the use of their child's data, including photographs, for research purposes and in publications. Surgery remains the main treatment option for all histological subtypes of thyroid cancer, however patients with distant metastasis are treated with radioactive iodine therapy. In this case, as adjuvant therapy, the patient received a combination of thyroidectomy and radioactive iodine therapy due to the presence of implantation metastases. Malignant transformation of ectopic thyroid tissue is extremely rare, and it may be difficult for a clinician to determine the best treatment option due to the lack of uniform treatment guidelines for this disease. This case report describes the clinical course of struma ovarii as well as an option for surgical treatment and adjuvant therapy for this disease.

  • Open Access

    Эктопия щитовидной железы в яичник с развитием папиллярного рака с канцероматозом. Описание клинического случая.

    by Полина Андреевна Наймушина, Денис Валерьевич Шевцов, Наталья Геннадьевна Ускова, Дмитрий Сергеевич Абрамов, Дмитрий Михайлович Коновалов, Дмитрий Гурамович Ахаладзе, Николай Сергеевич Грачев

    Pediatric Hematology/Oncology and Immunopathology | Peer-rewiev medical journal Вопросы гематологии/онкологии и иммунопатологии в педиатрии | Научный рецензируемый журнал

  • Open Access

    Using Regression Trees to Predict the Development of Immune-Mediated Adverse Events in Patients Receiving Immune Checkpoint Inhibitor Therapy

    by Наталья Владимировна Жукова, Рашида Вахидовна Орлова, Полина Андреевна Наймушина

    Введение. Токсичность ингибиторов иммунных контрольных точек в ряде случаев может быть крайне тяжёлой и даже приводить к летальному исходу. Цель. Поиск предиктивных маркеров токсичности иммунотерапии. Материалы и методы. В данной работе проанализированы данные 60 пациентов с солидными опухолями, получавших терапию ингибиторами иммунных контрольных точек на базе Санкт-Петербургского городского онкологического диспансера с 2018 до 2021 гг. Проводилось построение деревьев классификации для прогнозирования развития любого иммуноопосредованного нежелательного явления (иНЯ) на основе анализа возраста, пола, индекса массы тела, ECOG, экспрессии PD-L1, вида терапии, наличия сопутствующих заболеваний и оценки фракций лейкоцитов. Результаты. Построенное дерево решений позволяет прогнозировать риск иНЯ с чувствительностью 93 %, специфичностью — 66 %, положительной прогностической ценностью — 78,9 % и отрицательной ценностью — 73,3 %. Наиболее значимыми параметрами оказались экспрессия PD-L1 (на иммунных и опухолевых клетках) и возраст. Выводы. Экспрессия PD-L1 и возраст могут иметь предиктивный вес при прогнозировании риска возникновения иНЯ у больных, получающих терапию с применением ингибиторов иммунных контрольных точек.

  • Open Access

    Key differences between anti-PD-1/PD-L1 inhibitors

    by N. V. Zhukova, R. V. Orlova, E. A. Kaledina, P. A. Naymushina, A. M. Malkova, N. P. Beliak

    Indications to immunotherapy in cancer treatment continue to expand, thus there are more and more questions about clinical aspects of using different checkpoint inhibitors. Despite similar mechanism of action between widely used antibodies to PD-1 (nivolumab, pembrolizumab, prolgolimab) and PD-L1 (durvalumab, avelumab, atezolizumab), inhibitors are different due to features of monoclonal antibodies structure they are based on. For instance, toxicity leading to discontinuation of treatment occurs more frequently with anti-PD-L1 drugs than PD-1 inhibitors. On the contrary, the average incidence of any grade IRAEs was higher in patients treated with anti-PD-1 drugs. The revealed differences in the toxicity of the analyzed groups of drugs could be associated with the type of action of the drug. The feature of the PD-L1 inhibitors is more frequent occurrence of antibody-dependent cellular cytotoxicity reactions. However, PD-1 inhibitors showed a statistically significant survival benefit, according to a meta-analysis comparing anti-PD-1 and anti-PD-L1 groups. Besides data on differences in the efficacy and toxicity profiles of these agents, in this article we also analyze different issues in the structure of drug molecules, in particular, the role of LALA mutation in anti-PD-1 inhibitors. Understanding the key distinctive points of check-point inhibitors (CPI) in the future may allow to solve the problem of rechallenge and reintroduction after management of severe IRAEs.

  • Open Access

    Limitations and opportunities of cancer treatment in the COVID-19 pandemic

    by R. V. Orlova, E. A. Kaledina, A. M. Malkova, N. V. Zhukova, P. A. Naymushina, N. P. Beliak, A. E. Jukova, A. S. Sarmatova, N. A. Karaseva, I. V. Egorova, et al.

    The COVID-19 pandemic has affected all medical fields and brought up a lot of serious problems. The features of the COVID-19 infection in patients with cancer are important to understand. According to many articles, patients with cancer are more vulnerable to COVID-19 infection. Patients undergoing anticancer treatment have 1-4% morbidity rate. Patients with hematological diseases and lung cancer are at higher risk of SARS-CoV-2 infection and also have more severe symptoms and complications. In this article we discuss the effect of the tumors on the immune system and comprehend the pathogenesis of the coronavirus disease according to its impact on the immunity. Moreover, in the review we analyze available data about the influence of the different types of cancer therapy (chemotherapy, target therapy, radiotherapy and immunotherapy) on the severity of the COVID-19 infection. Evidence on the effect of chemotherapy on severity and mortality from COVID-19 is contradictory. Whereas there are some authors concluding that chemotherapy treatment is not affecting the severity of COVID-19 disease, there are also some works where the connection between these facts was established. At the same time target therapy, radio- and immunotherapy most likely do not worsen the SARS-CoV-2 infection and are not associated with the development of complications. But it’s important to say that the amount of data available for today is insufficient to make a unambiguous conclusion.